Fycompa approved for partial onset seizures
The FDA has approved Fycompa tablets to treat partial onset seizures in individuals aged 12 years and older who have epilepsy,
Drug Approvals
Bosutinib approved for chronic myelogenous leukemia
The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are resistant to or who cannot tolerate other therapies.
New drug approved for chemo-related severe neutropenia
The FDA has approved tbo-filgrastim to treat neutropenia in patients with nonmyeloid malignancies, who receive myelosuppressive chemotherapy.
Pediatric everolimus dose approved to treat rare brain tumor
The first pediatric form of the cancer drug everolimus has been sanctioned to treat rare brain tumors in children aged 1 year and older.
FDA approves Linzess for IBS, chronic constipation
Linzess sanctioned for constipation that does not respond to conventional treatment.
Once-daily pill approved to treat HIV
Stribild, a combination drug that only has to be taken once a day, interferes with enzymes that are needed for HIV to multiply.
Zaltrap approved for advanced colorectal cancer
The FDA has approved ziv-aflibercept (Zaltrap, Sanofi-Aventis) in combination with a FOLFIRI regimen for adults with advanced metastatic colorectal cancer.
Zetonna available soon for allergic rhinitis
Zetonna is a nasal aerosol approved to treat both ocular and nasal symptoms associated with seasonal allergic rhinitis (SAR), and nasal symptoms associated with perennial allergic rhinitis (PAR) in adults and adolescents aged >12 years.
Natazia approved for heavy menstrual bleeding
The FDA has approved the oral contraceptive, Natazia, to treat women with heavy menstrual bleeding that is not caused by a diagnosed condition of the uterus.
FDA approves respiratory distress drug for infants
Surfaxin (lucinactant) is indicated for the prevention of respiratory distress syndrome, a breathing disorder that affects premature infants.
- Loading...
Loading...
Loading... 
Loading...